-
Topotecan for Ovarian Cancer: Evidence and Limits
2026-08-24
The Cochrane review by Abudou and colleagues evaluated whether adding Topotecan to platinum–taxane chemotherapy improved outcomes in ovarian cancer. Its main contribution was to consolidate randomized evidence showing no clearly established survival advantage, while highlighting the clinical importance of treatment-related toxicity and the limits of extrapolating laboratory activity to patient benefit.
-
Phenylhydrazone ER Proteostasis Regulators
2026-08-23
This 2025 bioRxiv preprint identifies a covalent interaction between AA263-class phenylhydrazones and a subset of endoplasmic-reticulum protein disulfide isomerases, clarifying how these compounds activate ATF6-mediated proteostasis remodeling. Medicinal-chemistry analogs improved pathway activity and corrected trafficking defects in disease-associated alpha-1-antitrypsin and GABAA receptor models, while remaining subject to preprint-stage validation.
-
RCN2 Drives ESCC Metastasis and Cisplatin Resistance
2026-08-22
A 2025 study identifies RCN2 as a driver of esophageal squamous cell carcinoma metastasis and cisplatin resistance through UBR5-dependent PPP2CA degradation and PI3K-AKT activation. Its integrated omics, biochemical, cellular, and animal-model evidence positions the RCN2–UBR5–PPP2CA axis as a mechanistically defined target for ESCC cancer research.
-
L-NAME Hydrochloride for Vascular Research
2026-08-22
Use L-NAME Hydrochloride as a controlled nitric oxide synthase perturbation tool across organ-bath, cellular, and cardiovascular workflows. Its greatest value is mechanistic: it can distinguish NO-dependent relaxation from prostaglandin and receptor-linked responses when paired with rescue experiments and orthogonal readouts.
-
Ferroptosis Signature Identifies Atorvastatin in HCC
2026-08-21
A 2025 study integrated ferroptosis-related transcriptomics, survival modeling, and Connectivity Map screening to develop a four-gene prognostic signature for hepatocellular carcinoma (HCC) and identify Atorvastatin as a candidate treatment. In vitro and in vivo experiments supported atorvastatin-associated ferroptosis and suppression of HCC growth and migration, while also highlighting the need for independent validation before clinical translation.
-
WAY-100635: 5-HT1A Assay Workflow Guide
2026-08-20
This scenario-based guide explains how WAY-100635 (SKU A3933) can clarify 5-HT1A-dependent effects in receptor-binding, functional, and cell-based workflows. It covers solvent compatibility, controls, storage, interpretation, and practical vendor-selection criteria for reproducible serotonin receptor antagonist research.
-
Caspofungin Workflows for Candida Research
2026-08-20
Caspofungin provides a practical benchmark for probing fungal cell wall biosynthesis, profiling azole-resistant Candida, and validating antifungal assay design. This guide connects mechanism-focused in vitro workflows with the delayed-treatment model used to evaluate invasive Candida auris infection.
-
Dabigatran Evidence in Thromboembolic Disorders
2026-08-19
The 2015 review by Enriquez and colleagues examined dabigatran as the first widely introduced non-vitamin K oral anticoagulant, integrating pharmacology with evidence from atrial fibrillation, venous thromboembolism, and orthopedic prophylaxis. Its practical contribution is a balanced interpretation: dabigatran offers predictable anticoagulation and less routine monitoring, but renal elimination, P-glycoprotein interactions, and bleeding management remain decisive.
-
MitMAB for Organoid Endocytosis Research
2026-08-19
MitMAB enables dynamin-focused perturbation of extracellular vesicle uptake in polarized intestinal organoids, helping distinguish surface access from intracellular trafficking. This workflow combines a defined chemical inhibitor with apical-out, basal-out, and monolayer models for more mechanistic endocytosis research.
-
Machine Learning for Senolytic Discovery
2026-08-18
The reference study shows that cost-effective machine-learning models trained only on published screening data can identify senolytic candidates from chemical libraries. Validation in human cell systems identified ginkgetin, periplocin, and oleandrin, supporting data-efficient approaches to early-stage senolytic discovery while highlighting the need for careful cell-state and selectivity controls.
-
CAY10499: Human HSL Inhibitor Guide
2026-08-18
This scenario-based guide explains how CAY10499, a potent inhibitor of human hormone sensitive lipase and monoglyceride lipase, can improve the interpretation of lipid-linked viability, proliferation, and cytotoxicity experiments. It covers assay compatibility, dose selection, data interpretation, storage, and vendor reliability for SKU B7841.
-
Tunicamycin for ER Stress Research
2026-08-17
Tunicamycin is a practical N-glycosylation inhibitor for creating controlled ER stress models in macrophages and endothelial cells. This guide connects formulation, dose-timing design, inflammatory readouts, and the ATF6–TRIM10–NF-κB findings of a recent hepatectomy study.
-
Cefoperazone: From MIC Data to Model Design
2026-08-17
Cefoperazone sodium salt supports more than routine susceptibility testing. This article translates comparative MIC, bactericidal, β-lactamase, and biliary distribution evidence into better assay and infection-model decisions.
-
Eicosapentaenoic Acid: Assay Design and Mechanism
2026-08-16
Explore how Eicosapentaenoic Acid functions as an EPA omega-3 fatty acid in membrane, vascular, and lipid-oxidation assays. This guide also explains how recent arachidonic acid vaccine research informs—not validates—practical EPA assay design.
-
Topotecan (SKF104864) Assay Workflows
2026-08-15
Topotecan (SKF104864) gives cancer researchers a practical way to model topoisomerase I–dependent replication stress across glioma, pediatric tumor, and combination-treatment systems. This workflow-focused guide connects dose design, apoptosis readouts, cell-cycle analysis, and troubleshooting to reproducible in vitro experiments.